Skip to main content

Table 3 Relationship between baseline metabolite concentration and risk of prostate cancer after correction for multiple testing

From: Identification of metabolites associated with prostate cancer risk: a nested case-control study with long follow-up in the Northern Sweden Health and Disease Study

Age

Metabolite

Linear estimatesa

OR (95% CI) for quartilesb

OR (95% CI)

pcrude

Q1

Q2

Q3

Q4

Overall prostate cancer

 40–60 years

LPC C17:0

1.59 (1.21–2.08)

0.0007

1.00 (referent)

1.44 (1.07–1.96)*

1.43 (1.06–1.94)*

1.63 (1.20–2.21)*

LPC C18:0

1.59 (1.17–2.18)

0.0034

1.00 (referent)

1.08 (0.81–1.45)

1.32 (1.00–1.75)

1.36 (1.02–1.81)*

 40–50 years

Glycine

2.11 (1.21–3.69)

0.0084

1.00 (referent)

1.13 (0.70–1.83)

1.12 (0.70–1.81)

1.75 (1.09–2.82)*

Pyruvate

0.65 (0.48–0.89)

0.0066

1.00 (referent)

0.62 (0.40–0.97)*

1.04 (0.69–1.57)

0.46 (0.29–0.74)*

 60 years

LPC C17:0

2.08 (1.45–2.98)

< 0.0001*

1.00 (referent)

1.97 (1.29–3.01)*

2.10 (1.37–3.24)*

2.56 (1.67–3.93)*

LPC C18:0

1.83 (1.22–2.75)

0.0037

1.00 (referent)

0.95 (0.64–1.39)

1.30 (0.89–1.90)

1.54 (1.07–2.22)*

Aggressive prostate cancer

 40–60 years

LPC C17:0

2.67 (1.48–4.83)

0.0011

1.00 (referent)

1.64 (0.80–3.38)

2.69 (1.29–5.60)*

3.35 (1.66–6.76)*

PC ae C38:3

3.29 (1.50–7.24)

0.0030

1.00 (referent)

1.54 (0.77–3.10)

1.98 (0.96–4.12)

2.52 (1.28–4.97)*

PC ae C38:4

2.69 (1.25–5.76)

0.0110

1.00 (referent)

1.32 (0.68–2.56)

1.70 (0.85–3.39)

2.24 (1.17–4.29)*

LPC C20:4

1.99 (1.15–3.44)

0.0142

1.00 (referent)

1.24 (0.59–2.59)

1.98 (0.98–4.02)

2.13 (1.08–4.23)*

LPC C20:3

2.05 (1.12–3.75)

0.0206

1.00 (referent)

1.41 (0.76–2.61)

1.97 (1.03–3.77)*

1.83 (0.96–3.48)

PC ae C40:2

2.49 (1.25–4.97)

0.0095

1.00 (referent)

1.02 (0.54–1.94)

1.69 (0.90–3.18)

1.85 (1.00–3.41)*

C18:2

0.51 (0.29–0.89)

0.0167

1.00 (referent)

0.80 (0.46–1.40)

0.48 (0.25–0.92)*

0.55 (0.30–1.00)*

 60 years

LPC C17:0

3.02 (1.52–6.01)

0.0016

1.00 (referent)

1.63 (0.69–3.84)

2.17 (0.92–5.15)

3.90 (1.70–8.99)*

  1. Abbreviations: LPC lysophosphatidylcholine, PC phosphatidylcholine
  2. aListed metabolites were significant after correction for multiple testing (FDR 20%) according to p values (pcrude) from conditional logistic regression analyses using log2 transformed metabolite data (Additional file 3). Associations significant after the Bonferroni correction (for 148 independent tests; 0.05/148 = 0.000338) in the log2-based statistical analyses are indicated by the asterisk symbol (*)
  3. bThe listed metabolites were also analysed by conditional logistic regression using quartiles (details on the quartile-based statistical analyses are presented in Additional file 4). Associations with p value < 0.05 in the quartile-based statistical analyses are indicated by the asterisk symbol (*)
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us